发明名称 Quinazoline derivatives as VEGF inhibitors
摘要 The invention relates to quinazoline derivatives of formula (I),; wherein m is an integer from 1 to 3; R1 represents halogeno or C1-3alkyl; X1 represents —O—; R2 is selected from one of the following three groups: 1) C1-5alkylR3, wherein R3 is piperidinyl-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C1-4alkyl, C1-4hydroxyalkyl and C1-4alkoxy; 2) C2-5alkenylR3, wherein R3 is as defined herein; 3) C2-5alkynylR3, wherein R3 is as defined herein; and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation; pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
申请公布号 US9040548(B2) 申请公布日期 2015.05.26
申请号 US201414146954 申请日期 2014.01.03
申请人 AstraZeneca AB 发明人 Thomas Andrew Peter;Stokes Elaine Sophie Elizabeth;Hennequin Laurent Francois Andre
分类号 A01N43/54;A61K31/517;C07D239/72;C07D401/00;C07D401/12 主分类号 A01N43/54
代理机构 Morgan, Lewis & Bockius LLP 代理人 Morgan, Lewis & Bockius LLP
主权项 1. A method of treating breast cancer in a warm-blooded animal in need of such treatment which comprises administering to the animal an effective amount of 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline or a pharmaceutically acceptable salt thereof.
地址 Sodertalje SE